CD19 and neoplasm: CAR-T cell engineering aims to enhance T cell potency and overcome tumour immune evasion mechanisms by disrupting immune checkpoint proteins like PD-1 and CD19, while direct tumour editing seeks to disrupt oncogenic pathways or introduce tumour-suppressing genes.